Welcome to Paid Research Studies


Browse Locations ... United States» ... South Dakota» ... Aberdeen





  • Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer;   Stage III Rectal Cancer
    Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
    Interventions:   Drug: Fluorouracil;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)
    Recruiting - verified June 2017

  • Conditions:   Advanced Malignant Solid Neoplasm;   Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Plasma Cell Myeloma;   Refractory Malignant Neoplasm;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Afatinib;   Drug: Akt inhibitor AZD5363;   Drug: Binimetinib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Trk Inhibitor LOXO-101;   Drug: Vismodegib;   Drug: WEE1 Inhibitor AZD1775
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Condition:   Fatigue
    Interventions:   Drug: armodafinil 150 mg;   Other: Placebo;   Drug: armodafinil 250 mg
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified June 2017

  • Conditions:   Arthralgia;   Breast Cancer;   Hot Flashes;   Musculoskeletal Complications;   Sexual Dysfunction
    Interventions:   Drug: testosterone;   Other: placebo
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting - verified June 2017

  • Conditions:   Ductal Breast Carcinoma In Situ;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017

  • Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2017